These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10175989)

  • 1. Single European currency and Monetary Union. Macroeconomic implications for pharmaceutical spending.
    Kanavos P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):9-20. PubMed ID: 10175989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pros and cons of a single 'Euro-price' for drugs.
    Towse A
    Pharmacoeconomics; 1998 Mar; 13(3):271-6. PubMed ID: 10178652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The price of cigarettes in the European Union.
    Montes A; Villalbí JR
    Tob Control; 2001 Jun; 10(2):135-6. PubMed ID: 11387533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings.
    Kanavos P
    Pharmacoeconomics; 2000 Dec; 18(6):523-32. PubMed ID: 11227392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Euro debate offers a preview of health policy.
    Alcorn K
    J Int Assoc Physicians AIDS Care; 1997 Dec; 3(12):55. PubMed ID: 11364945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel imports of pharmaceuticals in the European Union.
    Darbà J; Rovira J
    Pharmacoeconomics; 1998; 14 Suppl 1():129-36. PubMed ID: 10186474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing a Fiscal Dialogue in Europe.
    Creel J
    Comp Econ Stud; 2021; 63(3):339-355. PubMed ID: 33746359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [European Monetary Union: Badly Prepared for Big Crises].
    Heine M; Herr H
    Wirtschaftsdienst; 2021; 101(5):369-375. PubMed ID: 34024950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adapting the EU Economic Governance to New Macroeconomic and Political Realities.
    Fargnoli R
    Inter Econ; 2020; 55(5):320-324. PubMed ID: 33132413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-COVID-19 EMU: Economic Distancing by Parallel Currencies.
    Mayer T; Schnabl G
    Inter Econ; 2020; 55(6):387-391. PubMed ID: 33281219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Union, economies and public health: not one without the other.
    Vervoort D; van Daalen KR
    Public Health; 2021 May; 194():1-3. PubMed ID: 33836317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debt Relief as a Last Resort for the Lender of Last Resort?: Monetary Financing - Doing It Right.
    Hansen A; Meyer D
    Inter Econ; 2021; 56(4):223-233. PubMed ID: 34376869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outstanding regulatory aspects in the European pharmaceutical market.
    Kanavos P; Mossialos E
    Pharmacoeconomics; 1999 Jun; 15(6):519-33. PubMed ID: 10538326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campaigners warn that EU trade deal with US could threaten drug prices.
    Watson R
    BMJ; 2014 Oct; 349():g6098. PubMed ID: 25294842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.